Overview and Lifecycle Management of Generic Pharmaceutical Drugs in Mexico, Guatemala and Brazil

  • Helly Kuveria K.B. Institute of Pharmaceutical Education and Research, Sector 23, Near GH 6, Gandhinagar, Gujarat, India
  • Zuki Patel
  • Manvendra Raval
  • Maitreyi Zaveri


Objective: The generic pharmaceutical markets in Mexico, Guatemala, and Brazil are influenced by distinct regulatory frameworks, production and distribution dynamics, and marketing strategies, which shape lifecycle management. Regulatory policies, market competition, and healthcare initiatives impact accessibility, affordability, and quality, presenting both challenges and opportunities for enhancement in these areas.

Summary: This thesis offers an in-depth examination of lifecycle management strategies in the generic pharmaceutical markets of Mexico, Guatemala, and Brazil. Generic drugs are crucial for increasing access to affordable healthcare, especially in emerging economies. Through comparative analysis, this research explores the regulatory frameworks, market dynamics, and key challenges in the development, approval, marketing, and post-marketing surveillance of generic drugs in these three Latin American countries.

The study starts with an overview of the regulatory landscape for generic pharmaceuticals in Mexico, Guatemala, and Brazil, highlighting similarities and differences in registration requirements, approval processes, and post-approval obligations. It investigates the roles of regulatory agencies like COFEPRIS, DIGEMID, and ANVISA in ensuring the quality, safety, and efficacy of generic drugs throughout their lifecycle. Additionally, the research delves into the strategies used by pharmaceutical companies for lifecycle management of generic drugs, including variations, biowaivers, and labeling changes.

Real-world case studies illustrate post-approval changes and their regulatory implications in each country, providing insights into the complexities of managing generic drug portfolios in different regulatory environments. The thesis also examines the market dynamics affecting the availability, pricing, and accessibility of generic drugs in Mexico, Guatemala, and Brazil. Factors such as patent expirations, competition, healthcare policies, and public procurement practices are analysed to understand their impact on market entry, competition, and the affordability of generic drugs. Furthermore, the study addresses the challenges and opportunities in pharmacovigilance and post-marketing surveillance of generic drugs, emphasizing the need for robust systems to detect and manage adverse drug reactions and ensure patient safety.

Conclusion: The key findings highlight regulatory frameworks, market dynamics, and lifecycle management strategies in the generic pharmaceutical markets, identifying challenges and opportunities. The study reflects on implications for stakeholders and suggests areas for future research to enhance accessibility, affordability, and quality.

Keywords: Generic pharmaceuticals, Lifecycle management, Regulatory framework, Market dynamics, Healthcare policies, Accessibility, Affordability, Quality assurance, Supply chain management, Patents, Post-marketing surveillance, Market competition


Download data is not yet available.


1. Geography of Mexico - Wikipedia [Internet]. Wikipedia; 2024 [cited 2024 May 14]. Available from:
2. The climatic zones in Mexico. Mexico has a wide range of climate zones... | Download Scientific Diagram [Internet]. Researchgate; 2012 Jun [cited 2024 May 14]. Available from:
3. Comisión Federal para la Protección contra Riesgos Sanitarios | Gobierno [Internet]. gob.mx; 2024 [cited 2024 May 14]. Available from:
4. Hayden, C. A Generic Solution?: Pharmaceuticals and the Politics of the Similar in Mexico. Current Anthropology. 2007;48(4):475–495. Doi: 10.1086/518301
5. Pharmexcil, Hyderabad. Pharmaceuticals Export Promotion Council of India Mexico Pharma Market & Regulatory Report; 2020.
6. Market penetration of generic drugs in Mexico and Brazil [Internet]. gabionline.net; 2023 Apr 27 [cited 2024 May 14]. Available from:
7. The Mexico Pharma Market: Growth factors and advantages for manufacturing | Tanner Pharma [Internet]. Tannerpharma; 2022 [cited 2024 May 14]. Available from:
8. Mexico Pharma Market - Chameleon Pharma Consulting [Internet]. chameleon-pharma;2023 [cited 2024 May 15]. Available from:
9. Mexico’s COFEPRIS [Internet]. [cited 2024 May 14]. Available from:
10. Drug Registration in Mexico | Regulatory Affairs in Latin America [Internet]. Latampharmara; 2024 [cited 2024 May 14]. Available from:
11. Generic life cycle of a pharmaceutical product | Download Scientific Diagram [Internet].Researchgate;2019 Jun [cited 2024 May 14]. Available from:
12. Shadlen KC. The Politics of Patents and Drugs in Brazil and Mexico: The Industrial Bases of Health Policies. Comparative Politics. 2009 Oct; 42(1):41-58(18).
doi: 10.5129/001041509X12911362972791
13. Flood, D., Mathieu, I., Chary, A. et al. Perceptions and utilization of generic medicines in Guatemala: a mixed-methods study with physicians and pharmacy staff. BMC Health Serv Res 17.2017;27. Doi
doi: 10.1186/s12913-017-1991-z.
14. Guatemala Credit Ratings: Fitch Ratings [Internet]. Fitchratings; 2024 [cited 2024 May 14]. Available from:
15. Brazil | History, Map, Culture, Population, & Facts | Britannica [Internet]. Britannica; 2024 [cited 2024 May 14]. Available from:
16. Brazil - Wikipedia [Internet]. Wikipedia; 2024 [cited 2024 May 15]. Available from:
17. Cardoso PA. GENERIC MEDICINES REGULATION IN BRAZIL. Int J Drug Reg Affairs [Internet]. 2017Sep.8 [cited 2024 May 23];5(3):1-. Available from:
18. The Brazilian Pharmacopeia — Agência Nacional de Vigilância Sanitária – ANVISA[Internet]. gov.br; 2020 Nov 03 [cited 2024 May 14]. Available from:
19. Brazil Impact on Pharma - Thematic Intelligence [Internet]. Globaldata; 2022 Dec 21 [cited 2024 May 14]. Available from:
20. Brazil Generic Drug Market to Grow at 6.7% During 2024-2032, Fostered by Favourable Government Initiatives [Internet]. Healthcare; 2019 Sep 26 [cited 2024 May 14]. Available from:
21. Huynh-Ba K, Beumer Sassi A. ANVISA: an introduction to a new regulatory agency with many challenges. AAPS Open [Internet]. 2018 Dec [cited 2024 May 14];4(1). Available from:
22. The pharmaceutical market in Brazil [Internet]. GENERICS AND BIOSIMILARS INITIATIVE; 2011 Dec 9 [cited 2024 May 14]. Available from:
23. da Fonseca EM, Shadlen KC. Promoting and regulating generic medicines: Brazil in comparative perspective. Rev Panam Salud Publica. 2017 Apr 20;41:e5. doi: 10.26633/RPSP.2017.5.
42 Views | 19 Downloads
How to Cite
Kuveria, H., Z. Patel, M. Raval, and M. Zaveri. “Overview and Lifecycle Management of Generic Pharmaceutical Drugs in Mexico, Guatemala and Brazil”. International Journal of Drug Regulatory Affairs, Vol. 12, no. 2, June 2024, pp. 65-72, doi:10.22270/ijdra.v12i2.676.

Most read articles by the same author(s)

1 2 3 > >>